---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-039409"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:25:17.547234+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q4 rev $71.7M (+51% YoY); MRD profitable; FY2026 MRD rev guide $255-265M

## Summary
- Q4 revenue $71.7M (+51% YoY); FY revenue $277.0M (+55% YoY); net loss narrowed to $13.6M and $59.5M.
- MRD segment achieved positive Adjusted EBITDA and cash flow; MRD revenue Q4 $61.9M (+54%), FY $212.3M (+46%).
- clonoSEQ test volume Q4 30,038 (+43% YoY); FY 105,587 (+39% YoY); expanded Medicare coverage in mantle cell lymphoma.
- Signed two non-exclusive immune receptor data licensing agreements with Pfizer.
- FY2026 guidance: MRD revenue $255-265M; total OpEx $350-360M; management expects company-wide profitability in 2026.

## SEC filing metadata
- accession: 0001193125-26-039409
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000119312526039409/0001193125-26-039409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000119312526039409/adpt-20260205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-039409
- JSON: https://secwatch.observer/filing/0001193125-26-039409.json
- Plain text: https://secwatch.observer/filing/0001193125-26-039409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.